Muhammad Imran Amirzada1,
Jian Jin1,2 
For correspondence:- Jian Jin Email: jinjian31@126.com Tel:+8651085918219
Received: 9 December 2011 Accepted: 23 October 2012 Published: 13 December 2012
Citation: Amirzada MI, Jin J. Therapeutic Applications of Interleukin 24 (IL24): A Review. Trop J Pharm Res 2012; 11(6):1023-1027 doi: 10.4314/tjpr.v11i6.20
© 2012 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Fisher’s group identified melanoma differentiation-associated protein-7 (MDA-7) upon discovery of cell surface receptor MDA-7 renamed Interleukin 24 (IL24).It has three N-glycosylation sites. IL24 signals through receptors. Binding of IL24 to receptors leads to the activation of STAT-3 and STAT-1. IL 24 induces the secretion of high level of Interferon Gamma (IFN-γ) ,IL6 and tumor necrosis factor alpha (TNF-α) and low levels of IL1,IL12 and granulocyte macrophage colony stimulating factor (GM-CSF) from human peripheral blood mononuclear cells(PBMC). IL24 has growth suppressive properties in a wide variety of human cancer cell lines without inducing harmful effects in normal cells. This review is focused on the role of IL 24 on tumor cell biology and its potential therapeutic applications.
Archives
News Updates
Fulltext in PDF